GFR90 has developed a wearable artificial kidney that provides ambulatory dialysis for use during daily activities. This addresses the significant medical, social, and economic issues which are created by the intermittency of in-clinic dialysis including the primary cause of death in dialysis patients, heart failure from fluid overload. GFR90 has secured a Canadian patent, has a US patent pending, has submitted EU and UK patents, and has successfully started clinical trials.

Event details

Date: September 18 - 20, 2023

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences


15 in total